Fennec Pharmaceuticals Inc. cash flow statement FENC

In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, Fennec Pharmaceuticals Inc. generated $50,000 of cash from operations, up 101.4% from the same quarter a year earlier.

USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the same quarter a year earlier.

Line
TTM
Jun 30, 2026
Q2 FY2026
Jun 30, 2026
Q1 FY2026
Mar 31, 2026
Q4 FY2025
Dec 31, 2025
Q3 FY2025
Sep 30, 2025
Q2 FY2025
Jun 30, 2025
Q1 FY2025
Mar 31, 2025
Q4 FY2024
Dec 31, 2024
Q3 FY2024
Sep 30, 2024
Operating
Stock-based compensation
8
+43.3%
2
+18.7%
1
+24.1%
3
+124.4%
2
+21.9%
1
+61.5%
1
-33.0%
1
+31.2%
2
+110.5%
Operating cash flow
-2
+82.5%
0
+101.4%
2
+155.1%
-6
-304.5%
1
+167.7%
-4
+56.1%
-4
-111.1%
-1
+69.7%
-2
+20.1%
Financing
Financing cash flow
25
+294.1%
1
+459.2%
1
+181.9%
21
+270.3%
2
+431.2%
-0
-210.5%
0
+131.7%
-12
-313.1%
-1
-362.7%
Change in cash
Net change in cash
23
+192.6%
1
+127.0%
3
+185.7%
15
+208.4%
3
+218.6%
-4
+51.2%
-4
-110.4%
-14
-1673.1%
-3
-6.8%
Ratios
Stock-based compensation to revenue
12.67%
9.93%
6.55%
18.31%
17.81%
15.48%
9.12%
14.18%
26.11%
Cash conversion
—
0.03x
11.84x
—
—
—
—
—
—
How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. The first column is the trailing twelve months through the latest quarter. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
FENC (Nasdaq)
Fiscal year ends
December 31
Incorporated in
British Columbia, Canada
Headquarters
Research Triangle Park, NC
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1211583
Former names
ADHEREX TECHNOLOGIES INC (until Aug 14, 2014)

Other Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.